6BX.F - Relevium Technologies Inc.

Frankfurt - Frankfurt Delayed Price. Currency in EUR
0.0165
-0.0010 (-5.71%)
At close: 5:00PM CET
Stock chart is not supported by your current browser
Previous Close0.0175
Open0.0175
Bid0.0165 x 1700000
Ask0.0275 x 1400000
Day's Range0.0165 - 0.0175
52 Week Range0.0130 - 0.0728
Volume14,000
Avg. Volume3,983
Market Cap3.328M
Beta (3Y Monthly)0.82
PE Ratio (TTM)N/A
EPS (TTM)-0.0290
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • GlobeNewswire

    Relevium Launches LeefyLyfe™ Organic Hemp Products in the US

    Relevium Technologies Inc. (TSX.V: “RLV”, OTCQB:“RLLVF” and Frankfurt: “6BX”) (the “Company” or “Relevium”), is pleased to announce the launch of LeefyLyfeTM Organics, a comprehensive line of organic health and wellness products formulated with broad spectrum organically sourced Scandinavian hemp. The carefully crafted premium line of organic hemp extracts are sourced from slow-grown hemp and extracted with CO2 and formulated with MCT oil and rich flavonoids to enhance overall well-being. The Company has launched a 1000Mg Organic Hemp Oil Drops with Citrus flavonoids and a 1000Mg Organic Hemp Gummy Bears with Wild Berry flavonoids, both part of an initial series of eight (8) products planned to be released over the next six months.

  • GlobeNewswire

    Relevium Executes LOI to Acquire Montreal Biopharma Contract Manufacturing Company

    Relevium Technologies Inc. (TSX.V: “RLV”, OTCQB:“RLLVF” and Frankfurt: “6BX”) (the “Company” or “Relevium”), is pleased to announce it has executed a letter of intent to acquire a Montreal based biopharma contract manufacturing company through its wholly owned subsidiary BGX e-Health LLC. The transaction is subject to customary due diligence and the parties have agreed to keep the vendors information confidential until such a time when the definitive agreement is executed. The target of the transaction is a Montreal based Biopharma company that manufactures for private label, white label and for its own brands of over the counter health products sold in Canada and the US.

  • GlobeNewswire

    Relevium Technologies Appoints Mark Billings as Chief Financial Officer

    Relevium Technologies Inc. (TSX.V: “RLV”, OTCQB:“RLLVF” and Frankfurt: “6BX”) (the “Company” or “Relevium”), is pleased to announce the appointment of Mark Billings, CFA as Chief Financial Officer for both Relevium and Biocannabix Health Corporation effective immediately. Mr. Billings replaces Faycal Salek who has resigned to pursue other opportunities. Mr. Billings is an experienced executive Chartered Financial Analyst and a graduate of the Harvard School of Business.

  • GlobeNewswire

    Relevium’s Subsidiary BGX E-Health Secures One Million Dollar Export Contract for the Middle East

    Relevium Technologies Inc. (TSX.V: “RLV”, OTCQB: “RLLVF” and Frankfurt: “6BX”) (the “Company” or “Relevium”), is pleased to announce that its wholly owned subsidiary, BGX E-Health LLC (“BGX”), has received a purchase order to supply Innova Health Care of Saudi Arabia with generic formulations totaling over CAD$1 Million. The Company has partnered with Montreal-based contract manufacturer BioV Pharma Inc., to fulfill the contract, which will be supplied in two shipments over the next six (6) months The first shipment, which totals approximately CAD$450,000 and is scheduled to be delivered before of the end of this year and the balance of the order is expected to be delivered during the first quarter of 2020.

  • GlobeNewswire

    Relevium Enters Into LOI to Unlock Value of Wholly Owned Subsidiary BGX E-Health LLC and Announces Conference Call With CEO

    Relevium Technologies Inc. (TSX.V: “RLV”, OTCQB:“RLLVF” and Frankfurt: “6BX”) (the “Company” or “Relevium”), is pleased to announce On October 25, 2019, the Company received a letter of intent (the “LOI”) to roll its interest in its wholly owned subsidiary BGX e-Health LLC into Newscope Capital Corporation (“Newscope”), a BC based privately held company seeking to become an aggregator in the wellness space, including CBD and hemp space. Under the preliminary terms of the LOI, Relevium with is expected to receive 20 Million shares of Newscope at $0.50 per share, representing approximately 86% of the resulting issuer.

  • GlobeNewswire

    Relevium Acquires 100% of Late Stage Processing and Medical Sales Applicant Weedsense

    Relevium Technologies Inc. (TSX.V: “RLV”, OTCQB:“RLLVF” and Frankfurt: “6BX”) (the “Company” or “Relevium”), is pleased to announce its wholly- owned subsidiary, Biocannabix (“BCX”), has executed an Agreement (the “Agreement”) to acquire 100% of the shares of Weedsense Inc. (“Weedsense”), a late stage applicant for a Standard Processing and Medical Sales license under the Cannabis Act, for an aggregate purchase price of $2,000,000 subject to the achievement of certain milestones. Weedsense is a Montreal- based business that will build a wholesale and distribution facility outside of the downtown core. Weedsense will be purchasing wholesale or bulk products from other Health Canada licensed producers or processors and will be distributing cannabis and cannabis-derived products directly to medical patients.

  • GlobeNewswire

    Relevium Enters Into Manufacturing Agreement With Bio V Pharma and Registers 400 NPN Numbers With Health Canada  

    Relevium Technologies Inc. (TSX.V: “RLV”, OTCQB: “RLLVF” and Frankfurt: “6BX”) (the “Company” or “Relevium”), is pleased to announce today that it has registered four hundred (400) Natural Product Numbers (NPNs) with Health Canada through its main brand, Bioganix®, and entered into a manufacturing agreement with Bio V Pharma Inc. (“Bio V Pharma”), to manufacture, label and package Bioganix® products. Bio V Pharma is a Quebec-based, full-service manufacturer of pharmaceutical and nutraceutical products including vitamins, botanical products, food and veterinary supplements and specializes in capsules, tablets, liquids and semi-solids delivered in a variety of packaging formats. The registration of the NPN numbers allows Bioganix® to enter the Canadian market with 400 Health Canada approved products.

  • GlobeNewswire

    Relevium Announces Intention to Spin-Out Pediatric Cannabis Subsidiary Biocannabix

    Management, the board of directors and its advisors are pleased to announce the Company’s intention to create additional value for its shareholders through a potential spin-off of its medical cannabis business, thus creating an independent, publicly-traded and vertically-integrated biopharma business focused on paediatric endomedicine with expected dividends for shareholders. CPG (Consumer Packaged Goods): Through its US based business, BGX E-Health LLC, the Company generates revenues from direct-to-consumer sales of health and wellness products through a portfolio of trusted brands. Paediatric Biopharma: Through its Canadian based business, Biocannabix, the Company is highly focused on the development of paediatric endomedical (cannabinoid) formulations with a strong operational footprint in Canada (sales, import/export and research), Colombia (cultivation, extraction and clinical development) and Germany (Licensing and Distribution).

  • GlobeNewswire

    Relevium Announces Results of Annual Meeting of Shareholders and Updates Other Regulatory Matters

    Relevium Technologies Inc. (TSX.V: “RLV”, OTCQB: “RLLVF” and Frankfurt: “6BX”) (the “Company” or “Relevium”), is pleased to announce the results of the Company's annual general and special meeting (the "AGM") held on September 6, 2019, in Montreal, Quebec.

  • GlobeNewswire

    Relevium Announces Record Sales From the Bioganix® Brand and Provides CBD Update

    Relevium Technologies Inc. (TSX.V: “RLV”, OTCQB: “RLLVF” and Frankfurt: “6BX”) (the “Company” or “Relevium”), is pleased to announce that the company hit a record high in monthly sales in the month of July 2019 for its Bioganix® branded OTC business. “This record high in monthly sales was driven primarily by higher customer subscriptions, awareness optimization in the UK and the successful and recent launch of PushPullSystemTM, CardiaPro® and VisionPro®, a new series of high-end wellness products.” stated Abis Hussain, Chief Marketing Officer at Relevium. The Company launched two exclusive, evidence-based formulations of Provinal® Omega 7 targeting heart health and vision care earlier last month and the products continue to gain initial acceptance by existing and new customers of the Bioganix® brand.

  • GlobeNewswire

    Relevium Signs Exclusivity Agreement With SOSCannabis.com for Reimbursement for Pediatric Patients

    Relevium Technologies Inc. (TSX.V: “RLV”, OTCQB: “RLLVF” and Frankfurt: “6BX”) (the “Company” or “Relevium”), announced today it has executed an exclusivity agreement to partner with SOS cannabis Inc. (“SOSCannabis”), which will provide pediatric customers with the ability to obtain free legal representation to seek reimbursement for the costs of medical cannabinoid therapy from different government agencies for the treatment of medical conditions for pediatric patients. The partnership agreement will provide Relevium’s pediatric customers with access to an experienced legal and case management team, who will prepare the case file and seek retroactive and prospective reimbursement for parents of pediatric patients at no cost.

  • GlobeNewswire

    Relevium’s CEO Issues Letter of Clarification to Shareholders  

    Relevium Technologies Inc. (TSX.V: “RLV”, OTCQB: “RLLVF” and Frankfurt: “6BX”) (the “Company” or “Relevium”), announced today a letter from Aurelio Useche, CEO to shareholders to clarify misconceptions and rumours in the market about a compliance news release disseminated on July 1, 2019 by the Company pursuant to a request from the OTC Markets Group. The Management of Relevium or any publicly traded company has the responsibility to dispel unfounded rumours, misinformation or false statements which result in unusual market activity. As CEO, director and shareholder of Relevium Technologies Inc. I feel it necessary to issue this letter and issue a clear and direct clarification regarding inaccurate and misleading statements being made by independent blog and referral traffic investor website equity.guru and Mr. Chris Parry.

  • GlobeNewswire

    Relevium Issues Statement Regarding Recent Promotional Activity

    Relevium Technologies Inc. (TSX.V: “RLV”, OTCQB: “RLLVF” and Frankfurt: “6BX”) (the “Company” or “Relevium”), announced today that it has been made aware of and requested by the OTC Markets Group, Inc. to comment on recent promotional activity concerning its common shares traded on the OTCQB market. On June 27th, 2019, the OTC Markets Group sent the Company copies of three newsletters sent on June 25 and June 26, 2019 by SmallCapFirm, a third-party marketing and awareness firm utilized by StockWireNews, LLC (“StockWireNews”), which in turn was utilized by one of the Company’s marketing firms, Shore Thing Media, LLC (“Shore Thing”).

  • GlobeNewswire

    Relevium’s Biocannabix Positions Itself as an Important Player in Colombia as it Pursues Endo-Medical Cannabis Strategy for Latin America

    Relevium Technologies Inc. a Health and Wellness portfolio company listed on TSX.V: “RLV”, OTCQB: “RLLVF” and Frankfurt: “6BX” (the “Company” or “Relevium”) announced today it is positioning itself as an important player in the Colombian medical cannabis market  by cementing medical and research relationships in the country in order to establish clinical validation programs for its Endo Nutraceutical Supplements (ENS) and Oral Nutritional Supplements. On June 13th, 2019, the Company announced a binding LOI to acquire LifeLine Pharma SAS, a binding agreement to acquire the shares of Lifeline Pharma SAS, a Cali based cultivation and extraction business in the burgeoning agro-pharma market in Colombia.

  • GlobeNewswire

    Relevium to Hold Investor Call to Discuss LATAM Strategy June 28, 2019 at 1:00pm EST

    Relevium Technologies Inc. a Health and Wellness portfolio company listed on TSX.V: “RLV”, OTCQB: “RLLVF” and Frankfurt: “6BX” (the “Company” or “Relevium”), is pleased to announce it will be holding a shareholder and investor conference call to discuss its Latin American (LATAM) strategy and the upside potential of its recently announced acquisition in Colombia. It is estimated that Colombia is positioned to supply about 44% of the World’s market for medical cannabis and the acquisition of Lifeline Pharma SAS  (“LifeLine”) in Colombia is set to allow Biocannabix Health Corporation to target two important sources of revenues: (1) EU GMP pharma-grade extracts for export and (2) endo-nutraceutical (ENS) and oral nutritional supplements (ONS) for in-country distribution.

  • GlobeNewswire

    Relevium Takes Major Step in Latam to Acquire Lifeline Pharma in Cali, Colombia

    Relevium Technologies Inc. (TSX.V: “RLV”, OTCQB: “RLLVF” and Frankfurt: “6BX”) (the “Company” or “Relevium”), is pleased to announce that Biocannabix Health Corporation (“Biocannabix”), a wholly-owned subsidiary of Relevium has executed on June 12, 2019 a binding agreement to acquire the shares of Lifeline Pharma SAS, a Cali based cultivation and extraction business in the burgeoning agro pharma market in Colombia. Multi-stage project with (1) an initial 5 hectares that includes the local offices, a laboratory, a fully enclosed greenhouse for tissue culture and micropropagation and an initial cultivation of over 200,000 square feet in open air green houses, (2) an option to expand to an additional 20 hectares or 2.2 million square feet of open air greenhouse cultivation and (3) the possibility to expand to another additional 60 hectares or 6.5 million square feet of cultivation.

  • GlobeNewswire

    Relevium Closes Private Placement Financing

    Relevium Technologies Inc. (TSX.V: “RLV”, OTCQB: “RLLVF” and Frankfurt: “6BX”) (the “Company” or “Relevium”), is pleased to announce that it has closed a non-brokered private placement financing for a total of 15,350,000 units (the "Units") at $0.08 per Unit, for total gross proceeds of $1,228,000. Each Unit consists of one common share of Relevium and one common share purchase warrant entitling the holder to purchase one additional common share at $0.12 per share for a period of one year from the date of the issue. Relevium has the right to accelerate the expiry date of the Warrants if, at any time, the average closing price of Relevium’s common shares is equal to or greater than $0.15 for 10 consecutive trading days.

  • GlobeNewswire

    Relevium’s Biocannabix Executes LOI to Acquire 30% Interest in Weedsense, a Late Stage Applicant for Standard Processing and Medical Sales License

    Relevium Technologies Inc. (TSX.V: “RLV”, OTCQB: “RLLVF” and Frankfurt: “6BX”) (the “Company” or “Relevium”), is pleased to announce its wholly owned subsidiary Biocannabix Health Corporation (“Biocannabix”) has executed an LOI to acquire 30% of Weedsense Inc., a late stage applicant for standard processing and medical sales license. Weedsense Inc. (“Weedsense”) is building a wholesale and distribution business in Montreal, Québec.

  • GlobeNewswire

    Relevium Provides Corporate Update on Its Medical Cannabis Strategy

    Relevium Technologies Inc. (TSX.V: “RLV”, OTCQB: “RLLVF” and Frankfurt: “6BX”) (the “Company” or “Relevium”), is pleased to provide a corporate update on the Company’s positioning and strategy regarding medical cannabis and CBD Nutraceuticals. The Food and Drug Administration (the “FDA”), held a key public hearing last Friday regarding its role in regulating cannabis-derived products such as CBD as nutritional supplements. The FDA’s position is that although hemp is no longer an illegal substance under federal law, the FDA continues to regulate cannabis products under the Food, Drug, and Cosmetic Act (“FD&C Act”) and Section 351 of the Public Health Service Act.

  • GlobeNewswire

    Relevium Launches New Line of High-End Omega Fish Oils Targeting Inflammation, Heart and Vision    

    Relevium Technologies Inc. (TSX.V:“RLV”, OTCQB:“RLLVF” and Frankfurt: “6BX”) (the “Company” or “Relevium”), is pleased to announce that its OTC business has launched a new line of omega fish oils based formulations targeting inflammation, heart and vision care. The Company has launched an initial two omega formulated products to support heart health and vision care: CardiaProtm and VisionProtm, leading the way to a complete line of scientifically formulated products targeting inflammation. Inflammation, which is a process by which the body's natural immune response seeks to protect us from infection with foreign organisms, such as bacteria and viruses.

  • GlobeNewswire

    Relevium Announces Private Share Purchase by CEO

    Relevium Technologies Inc. (TSX.V:“RLV”, OTCQB:“RLLVF” and Frankfurt: “6BX”) (the “Company” or “Relevium”), announced today that Mr. Aurelio Useche, Chief Executive Officer, has agreed to purchase a total of 4,213,713 common shares of Relevium, representing approximately 3% of Relevium’s total shares outstanding, from Mr. Albertus Engelbrecht in a private transaction. Relevium is a publicly-traded company that operates in the health and wellness industry, including legal cannabis, with a primary focus on online distribution. The principal business of the Company is the identification, evaluation, acquisition and operations of brands and businesses in the Health and Wellness markets and medical cannabis.

  • GlobeNewswire

    Relevium Announces Reprice of the 2016 and 2017 Series Warrants

    Relevium Technologies Inc. (TSX.V:“RLV”, OTCQB:“RLLVF” and Frankfurt: “6BX”) (the “Company” or “Relevium”), announced the re-pricing 12,398,500 warrants series 2017 with an original exercise price of $0.15 and expiring June 16, 2019 and 3,258,000 warrants of series 2016 with an original exercise price of $0.15 and expiring August 16, 2019. The series 2016 and 2017 have been repriced to $0.10 and the new exercise price is only valid for a period of 29 days starting today and expiring June 15, 2019. The warrant re-price is subject to final approval by the TSX Venture Exchange.

  • GlobeNewswire

    Relevium Reports Second Quarter Revenue Bounce Back for Fiscal 2019  

    Relevium Technologies Inc. (TSX.V:“RLV”, OTCQB:“RLLVF” and Frankfurt: “6BX”) (the “Company” or “Relevium”), is pleased to report second quarter results for fiscal 2019. During the second quarter ended December 2018, the Company’s revenue bounced back to $1,006,501 as compared to $968,474 in the second quarter of fiscal 2018. The Company also reported quarter-over-quarter increase in revenues from $985,051 reported for the first quarter of fiscal 2019.

  • GlobeNewswire

    Relevium Announces DTC Eligibility for the US Market

    Relevium Technologies Inc. (TSX.V: “RLV”,  OTC: “RLLVF” and Frankfurt: “6BX”) (the “Company” or “Relevium”) is pleased to announce it has secured eligibility by The Depository Trust Company (DTC) for its shares on the OTC. DTC is a subsidiary of the Depository Trust & Clearing Corp. that manages the electronic clearing and settlement of publicly traded companies in the United States. DTC eligibility will simplify the process of trading and is expected to enhance liquidity and overall visibility in the US OTC capital markets, where the Company trades under the symbol "RLLVF".

  • GlobeNewswire

    Relevium Launches the Push and Pull System™, Targeting a New Revenue Stream in the Burgeoning Cosmeceutical Market

    Relevium Technologies Inc. (TSX.V: “RLV”,  OTC: “RLLVF” and Frankfurt: “6BX”) (the “Company” or “Relevium”), is pleased to announce the new launch of the Push and Pull System™, an innovation in delivering a comprehensive solution for skin care, designed specifically for today’s active women. The Push & Pull System™ by Bioganix® is the first ever comprehensive natural anti-aging system for complete skin care that combines Collagen Protein supplements (PUSH) and naturally sourced Aloe Vera skin anti-aging cream (PULL). This new launch is targeting a brand-new revenue stream in the burgeoning cosmeceutical market, which is the fastest growing segment of the health and wellness Market.